<?xml version="1.0" encoding="UTF-8"?>
<p>Cannabinoids are of significant interest recently, especially non-psychoactive phytocannabinoids such as CBD, as the market expanded dramatically [
 <xref rid="B11-molecules-25-03943" ref-type="bibr">11</xref>]. Recently, there has been a flash of research articles on CBD effects on human health [
 <xref rid="B9-molecules-25-03943" ref-type="bibr">9</xref>,
 <xref rid="B11-molecules-25-03943" ref-type="bibr">11</xref>,
 <xref rid="B47-molecules-25-03943" ref-type="bibr">47</xref>]. Previous research has shown that CBD has anti-epileptic, anti-inflammatory, and anti-psychotic properties [
 <xref rid="B48-molecules-25-03943" ref-type="bibr">48</xref>] and against neurodegenerative diseases [
 <xref rid="B9-molecules-25-03943" ref-type="bibr">9</xref>]. A recent review summarized the various molecular pathways that cause positive effects of CBD, especially with respect to the major neurodegenerative disorders [
 <xref rid="B9-molecules-25-03943" ref-type="bibr">9</xref>]. The author elaborated on published data that support the notion of CBD as a potential pharmacological tool for the treatment of such disorders, and CBD safety as a potential therapeutic agent [
 <xref rid="B9-molecules-25-03943" ref-type="bibr">9</xref>].
</p>
